子痫前期胎盘组织中Endoglin、PAI-1、Flt-1蛋白的表达及临床意义探讨  

Expressions and clinical significance of Endoglin,PAI-1 and Flt-1 proteins in placenta of preeclampsia

作　　者：肖欢 梅军华 张志安[1] 刘韵[2] 张雅君 XIAO Huan;MEI Jun-hua;ZHANG Zhi-anl;LIU Yun;ZHANG Ya-jun(Department of Obstetrics and Gynecology,Huanggang Central Hospital,Huanggang,Hubei 438000,China;Department of Obstetrics and Gynecology,Xiangyang Central Hospital,Affiliated Hospital of Hubei University of Arts and Sciences,Xiangyang,Hubei 441021,China)

机构地区：[1]黄冈市中心医院妇产科,湖北黄冈438000 [2]襄阳市中心医院妇产科,湖北文理学院附属医院,湖北襄阳441021

出　　处：《中国优生与遗传杂志》2019年第7期830-833,F0002,共5页Chinese Journal of Birth Health & Heredity

基　　金：湖北省卫计委基金,编号:WJ2015MA024

摘　　要：目的检测子痫前期胎盘组织中内皮糖蛋白(Endoglin)、纤溶酶原激活物抑制剂-1(PAI-1)、血管内皮生长因子受体1(Flt-1)蛋白的表达,并分析其临床意义。方法对80例子痫前期患者和80例健康孕妇的临床资料进行回顾性分析,分别记为疾病组和健康组,均在医院妇产科分娩,且均保存胎盘组织并采用免疫组化法(SP)检测Endoglin、PAI-1、Flt-1蛋白阳性表达率,并分析上述蛋白表达的临床意义。结果疾病组Endoglin、PAI-1、Flt-1蛋白表达阳性率明显高于健康组(P<0.05);疾病组重度、治疗无效、胎儿生长受限、死胎、早产、新生儿死亡、新生儿低体质量患者胎盘组织中Endoglin、PAI-1、Flt-1蛋白阳性表达率均明显高于疾病组轻度、治疗有效、胎儿生长正常、活产、足月产、新生儿存活、非新生儿低体质量患者胎盘组织中Endoglin、PAI-1、Flt-1蛋白阳性表达率(P<0.05);围产儿不良妊娠结局发生率为25.00%,经Logistic回归分析可知,母体高龄、重度子痫前期、胎盘组织Endoglin、PAI-1、Flt-1蛋白阳性表达均是子痫前期患者围产儿不良妊娠结局的危险因素(OR=4.596、5.833、6.812、6.704、7.805,P<0.05)。结论在子痫前期胎盘组织中Endoglin、PAI-1、Flt-1蛋白阳性表达率高,且与严重程度、治疗效果、围产儿不良妊娠结局等均有关,母体高龄、重度子痫前期及胎盘组织Endoglin、PAI-1、Flt-1蛋白阳性表达等均是围产儿不良妊娠结局的危险因素。Objective:To detect the expression of endothelial glycoprotein(Endoglin),plasminogen activator inhibitor-1(PAI-1)and vascular endothelial growth factor receptor-1(Flt-1)in placenta of preeclampsia and to analyze on their clinical significance. Methods:The clinical data of 80 patients with preeclampsia and 80 healthy pregnant women were retrospectively analyzed. They were recorded as disease group and healthy group. All of them were delivered in gynecology and obstetrics department of hospital. The placenta tissues were preserved and the positive expression rates of Endoglin,PAI-1 and Flt-1 proteins were detected by immunohistochemical method(SP). The clinical significance of expressions of these proteins was analyzed.Results:The positive rates of Endoglin,PAI-1 and Flt-1 protein expressions in the disease group were significantly higher than those in the healthy group(P<0.05). The positive expression rates of Endoglin,PAI-1 and Flt-1 protein in placenta of patients with severe disease,ineffective treatment,fetal growth restriction,stillbirth,premature delivery,neonatal death and low birth weight were significantly higher than the positive expression rates of Endoglin,PAI-1 and Flt-1 protein in placenta of patients with mild disease,effective treatment,normal fetal growth,live birth,full-term birth,neonatal survival and non-neonatal low body mass(P<0.05). The incidence of perinatal adverse pregnancy outcomes was 25.00%. Logistic regression analysis showed that maternal age,severe illness,positive expressions of Endoglin,PAI-1 and Flt-1 proteins in placenta were risk factors for adverse perinatal pregnancy outcomes in preeclampsia patients(OR=4.596,5.833,6.812,6.704,7.805,P<0.05). Conclusion:The positive expression rates of Endoglin,PAI-1 and Flt-1 protein in placenta of preeclampsia were high,which were related to the severity,therapeutic effect and adverse pregnancy outcomes of perinatal infants. Maternal age,maternal hypertension and positive expressions of Endoglin,PAI-1 and Flt-1 proteins in placenta were risk

关 键 词：子痫前期 胎盘组织 内皮糖蛋白 纤溶酶原激活物抑制剂 血管内皮生长因子受体-1 

分 类 号：R714.245[医药卫生—妇产科学]